Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCAX NASDAQ:CPRX NASDAQ:GMTX NASDAQ:IMVT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCAXBicara Therapeutics$11.90-0.3%$10.74$7.80▼$28.09$649.26MN/A585,589 shs376,731 shsCPRXCatalyst Pharmaceuticals$20.54-0.2%$20.99$19.00▼$26.58$2.51B0.851.31 million shs1.50 million shsGMTXGemini Therapeutics$59.650.0%$57.76$1.16▼$14.10$2.58B-0.12189,291 shs214,790 shsIMVTImmunovant$15.07+2.6%$16.29$12.72▼$34.47$2.63B0.451.45 million shs1.34 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCAXBicara Therapeutics0.00%+5.48%+13.39%+8.45%+1,193,999,900.00%CPRXCatalyst Pharmaceuticals0.00%-0.15%-2.51%-17.34%+1.68%GMTXGemini Therapeutics0.00%-1.17%+1.14%+24.96%+17.37%IMVTImmunovant0.00%-1.34%-6.49%-4.86%-52.46%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCAXBicara TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACPRXCatalyst Pharmaceuticals4.9027 of 5 stars3.62.00.03.92.73.33.8GMTXGemini TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AIMVTImmunovant2.4974 of 5 stars4.41.00.00.02.31.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCAXBicara Therapeutics 3.00Buy$32.25171.02% UpsideCPRXCatalyst Pharmaceuticals 3.13Buy$33.2061.64% UpsideGMTXGemini Therapeutics 0.00N/AN/AN/AIMVTImmunovant 2.83Moderate Buy$35.20133.58% UpsideCurrent Analyst Ratings BreakdownLatest BCAX, GMTX, IMVT, and CPRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/22/2025BCAXBicara TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$41.00 ➝ $40.008/19/2025CPRXCatalyst PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/18/2025BCAXBicara TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$36.008/12/2025BCAXBicara TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$30.008/12/2025IMVTImmunovantJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$40.00 ➝ $37.008/12/2025IMVTImmunovantBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$33.00 ➝ $30.008/11/2025IMVTImmunovantCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy7/28/2025IMVTImmunovantUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$17.00 ➝ $18.007/10/2025IMVTImmunovantThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold$18.006/5/2025CPRXCatalyst PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 9/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCAXBicara TherapeuticsN/AN/AN/AN/A$9.04 per shareN/ACPRXCatalyst Pharmaceuticals$491.73M5.11$2.44 per share8.42$6.10 per share3.37GMTXGemini TherapeuticsN/AN/AN/AN/A$2.89 per shareN/AIMVTImmunovantN/AN/AN/AN/A$4.16 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCAXBicara Therapeutics-$68M-$3.17N/AN/AN/AN/A-21.67%-20.89%11/11/2025 (Estimated)CPRXCatalyst Pharmaceuticals$163.89M$1.6512.459.640.8437.36%40.78%35.36%11/5/2025 (Estimated)GMTXGemini Therapeutics-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/AIMVTImmunovant-$413.84M-$2.85N/AN/AN/AN/A-80.99%-72.23%11/6/2025 (Estimated)Latest BCAX, GMTX, IMVT, and CPRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025BCAXBicara Therapeutics-$0.54-$0.50+$0.04-$0.50N/AN/A8/11/2025Q1 2026IMVTImmunovant-$0.69-$0.60+$0.09-$0.71N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCAXBicara TherapeuticsN/AN/AN/AN/AN/ACPRXCatalyst PharmaceuticalsN/AN/AN/AN/AN/AGMTXGemini TherapeuticsN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCAXBicara TherapeuticsN/A25.8025.80CPRXCatalyst PharmaceuticalsN/A6.716.55GMTXGemini TherapeuticsN/A71.4971.49IMVTImmunovantN/A12.3212.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCAXBicara TherapeuticsN/ACPRXCatalyst Pharmaceuticals79.22%GMTXGemini Therapeutics75.42%IMVTImmunovant47.08%Insider OwnershipCompanyInsider OwnershipBCAXBicara TherapeuticsN/ACPRXCatalyst Pharmaceuticals10.40%GMTXGemini Therapeutics12.90%IMVTImmunovant1.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCAXBicara Therapeutics3254.56 millionN/AN/ACPRXCatalyst Pharmaceuticals80122.39 million109.66 millionOptionableGMTXGemini Therapeutics3043.33 million37.74 millionNot OptionableIMVTImmunovant120174.32 million171.18 millionOptionableBCAX, GMTX, IMVT, and CPRX HeadlinesRecent News About These CompaniesImmunovant, Inc. $IMVT Holdings Boosted by Alpine Global Management LLCSeptember 2 at 8:55 AM | marketbeat.comRafferty Asset Management LLC Acquires 22,213 Shares of Immunovant, Inc. $IMVTSeptember 2 at 5:05 AM | marketbeat.comDAFNA Capital Management LLC Purchases 62,000 Shares of Immunovant, Inc. $IMVTSeptember 1 at 7:26 AM | marketbeat.com233,985 Shares in Immunovant, Inc. $IMVT Purchased by Nuveen LLCAugust 30 at 3:41 AM | marketbeat.comRoivant Sciences (ROIV) Announces Q1 2025 Business UpdateAugust 29, 2025 | finance.yahoo.comAnalysts Set Immunovant, Inc. (NASDAQ:IMVT) Target Price at $35.20August 29, 2025 | americanbankingnews.comImmunovant Stockholders Approve Key Governance DecisionsAugust 28, 2025 | tipranks.comImmunovant, Inc. $IMVT Shares Purchased by Affinity Asset Advisors LLCAugust 28, 2025 | marketbeat.comJump Financial LLC Raises Stock Holdings in Immunovant, Inc. $IMVTAugust 28, 2025 | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) Receives Consensus Rating of "Moderate Buy" from AnalystsAugust 28, 2025 | marketbeat.comIMVT Investors Have Opportunity to Join Immunovant, Inc. Fraud Investigation with the Schall Law FirmAugust 27, 2025 | businesswire.comCharles Schwab Investment Management Inc. Grows Position in Immunovant, Inc. $IMVTAugust 26, 2025 | marketbeat.comSwiss National Bank Acquires 30,800 Shares of Immunovant, Inc. $IMVTAugust 25, 2025 | marketbeat.comT. Rowe Price Investment Management Inc. Increases Holdings in Immunovant, Inc. $IMVTAugust 24, 2025 | marketbeat.comVanguard Group Inc. Raises Stock Holdings in Immunovant, Inc. $IMVTAugust 24, 2025 | marketbeat.comAberdeen Group plc Increases Stock Position in Immunovant, Inc. $IMVTAugust 21, 2025 | marketbeat.comDeutsche Bank AG Raises Stake in Immunovant, Inc. (NASDAQ:IMVT)August 18, 2025 | marketbeat.comTejara Capital Ltd Makes New Investment in Immunovant, Inc. (NASDAQ:IMVT)August 17, 2025 | marketbeat.comQ2 Earnings Estimate for Immunovant Issued By HC WainwrightAugust 16, 2025 | marketbeat.comQ2 EPS Estimates for Immunovant Decreased by Leerink PartnrsAugust 16, 2025 | marketbeat.comLifesci Capital Predicts Immunovant Q2 EarningsAugust 16, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBCAX, GMTX, IMVT, and CPRX Company DescriptionsBicara Therapeutics NASDAQ:BCAX$11.90 -0.04 (-0.34%) Closing price 04:00 PM EasternExtended Trading$11.90 -0.01 (-0.04%) As of 06:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.Catalyst Pharmaceuticals NASDAQ:CPRX$20.54 -0.05 (-0.24%) Closing price 04:00 PM EasternExtended Trading$20.67 +0.13 (+0.63%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.Gemini Therapeutics NASDAQ:GMTX$59.64 -0.02 (-0.03%) As of 08/29/2025Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.Immunovant NASDAQ:IMVT$15.07 +0.38 (+2.59%) Closing price 04:00 PM EasternExtended Trading$15.30 +0.23 (+1.53%) As of 05:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Loop Industries Insiders Buy Stock, Signal Confidence in Outlook Joby Aviation's Pullback: A Gift for Investors Who See the Future Kohl’s Stock Rebound Faces a Showdown With Short Sellers What to Watch for From D-Wave Now That Earnings Are Done Alibaba Rallies on New AI Chip Design, Sending NVIDIA Stock Lower 3 High-Yield Stocks Just Supercharged Their Dividends MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
